Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.61 |
| ▸ | MMP8 | P22894 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8874156 | 0.84 | BCHE (0.58) | GAAKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL29592808 | 0.83 | ALDH1A1 (0.49) | RIPK1MMP8SMN1; SMN2OPRK1ALDH1A1 | |
| SCHEMBL10990271 | 0.82 | RIPK1 (0.68) | RIPK1MMP8GAAKMT2ACYP2C19 | |
| SCHEMBL624536 | 0.81 | CYP2C9 (0.65) | RIPK1KMT2ACYP2C19MEN1CYP2C9 | |
| SCHEMBL625014 | 0.81 | TPSAB1 (0.61) | KMT2ACYP2D6CYP2C19MEN1CYP1A2 | |
| SCHEMBL4963071 | 0.81 | LMNA (0.56) | KMT2ACYP2C19CYP1A2SMN1; SMN2ALDH1A1 | |
| SCHEMBL3116602 | 0.81 | RIPK1 (0.57) | RIPK1MMP8GAAKMT2ACYP2D6 | |
| SCHEMBL30471275 | 0.80 | RIPK1 (0.61) | RIPK1MMP8GAAKMT2ACYP2D6 | |
| SCHEMBL1516186 | 0.80 | RIPK1 (0.71) | RIPK1MMP8GAAKMT2ACYP2D6 | |
| SCHEMBL4765237 | 0.80 | RIPK1 (0.61) | RIPK1MMP8GAAKMT2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113880799-A | Intermediate compound for preparing paclitaxel, synthesis method thereof and synthesis method of paclitaxel | 南方科技大学 | 2022-01-04 | — | — | CN | claimed |
| CN-107899539-A | There is magnetic montmorillonite being modified based on sodium of adsorption function and preparation method thereof to caesium | 北京源清益壤环保科技有限公司 | 2018-04-13 | — | — | CN | claimed |
| CN-105623007-A | High-temperature-resistant and ageing-resistant cable sheath material and preparing method thereof | SUZHOU KEMAO ELECTRONIC MAT TECH CO LTD | 2016-06-01 | — | — | CN | claimed |
| EP-2106403-A2 | FUNCTIONALIZED BETA 1,6 GLUCOSAMINE DISACCHARIDES AND PROCESS FOR THEIR PREPARATION | OM Pharma (CH) | 2009-10-07 | — | — | EP | claimed |
| WO-2008059035-A2 | FUNCTIONALIZED BETA 1,6 GLUCOSAMINE DISACCHARIDES AND PROCESS FOR THEIR PREPARATION | OM PHARMA (CH) | 2008-05-22 | — | — | WO | claimed |
| WO-2008059307-A2 | FUNCTIONALIZED BETA 1,6 GLUCOSAMINE DISACCHARIDES AND PROCESS FOR THEIR PREPARATION | OM PHARMA (CH) | 2008-05-22 | — | — | WO | claimed |
| EP-1315559-B1 | APPARATUS AND METHODS FOR THE AUTOMATED SYNTHESIS OF OLIGOSACCHARIDES | MASSACHUSETTS INST TECHNOLOGY (US) | 2006-03-22 | — | — | EP | claimed |
| EP-0660835-A4 | PROCESS FOR PREPARING CERTAIN PYRROLO 3,4- -I(B))QUINOLINES, CERTAIN 1H-PYRANO 3',4':6,7)INDOLIZINO 1,2--I(B))QUINOLIN-3,14(4H,12H)-DIONES, AND CERTAIN 8-METHYL-7-(OXOPROPYL)-INDOLIZINO 1,2--I(B))QUINOLIN-9(11H)-ONES. | — | 1995-08-16 | — | — | EP | claimed |
| EP-0660835-A1 | PROCESS FOR PREPARING CERTAIN PYRROLO 3,4- $i(b)]QUINOLINES, CERTAIN 1H-PYRANO 3',4':6,7]INDOLIZINO 1,2-$i(b)]QUINOLIN-3,14(4H,12H)-DIONES, AND CERTAIN 8-METHYL-7-(OXOPROPYL)-INDOLIZINO 1,2-$i(b)]QUINOLIN-9(11H)-ONES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-07-05 | — | — | EP | claimed |
| EP-3735975-B1 | ERTUGLIFLOZIN FOR USE IN TREATING HEART FAILURE IN PATIENTS WITH DIABETES | MERCK SHARP & DOHME LLC (US) | 2025-12-03 | — | — | EP | disclosed |
| CN-118652195-A | Process for producing chloro acetonitrile | 江苏中科嘉骥智能制造有限公司 | 2024-09-17 | — | — | CN | disclosed |
| US-12036203-B2 | Methods of treating or reducing the risk of cardiovascular events and related diseases using SGLT-2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-07-16 | — | — | US | disclosed |
| CN-118265691-A | Cyclohexylbeta-hydroxyalkylamines and their medical use | 阿托基公司 | 2024-06-28 | — | — | CN | disclosed |
| EP-4232438-A1 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | The Governors of the University of Alberta (CA) | 2023-08-30 | — | — | EP | disclosed |
| WO-1994009010-A1 | O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNOSUPPRESSANTS | SANDOZ LTD. (CH) | 1994-04-28 | — | — | WO | disclosed |
| WO-1994002134-A1 | CHOLESTEROL-LOWERING AGENTS | MERCK & CO., INC. (US) | 1994-02-03 | — | — | WO | disclosed |
| US-5264605-A | Myoinsitol derivatives, process for preparing same, phosphorylating agent, and its utilization | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1993-11-23 | — | — | US | disclosed |
| EP-0505868-A2 | N-Acyl-alpha-aminoacids derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-09-30 | — | — | EP | disclosed |
| EP-0443449-A2 | Process for the preparation of oxetanones | F. HOFFMANN-LA ROCHE AG (CH) | 1991-08-28 | — | — | EP | disclosed |
| EP-0431197-A1 | MYOINOSITOL DERIVATIVE AND METHOD OF PRODUCTION THEREOF, AND PHOSPHORYLATING AGENT AND ITS USE | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1991-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036203-B2 | Methods of treating or reducing the risk of cardiovascular events and related diseases using SGLT-2 inhibitors | SLC5A1, SLC5A2, GLP1R | RIPK1 1511/4885MMP8 1199/4885GAA 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.